Multidimensional Rehabilitation Programs for Cognitive Impairment in Comorbid Outpatients: a Randomized Controlled Trial
Launched by ISTITUTI CLINICI SCIENTIFICI MAUGERI SPA · Jul 13, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how different rehabilitation programs can help improve thinking and memory skills in older adults who have cognitive impairment, particularly those with issues related to vascular diseases and other health conditions. The study will compare three types of rehabilitation: one that uses digital tools along with physical exercises, another that uses paper-based exercises with physical activities, and a third that focuses only on physical exercises. The goal is to find out which approach works best to enhance cognitive functions and overall well-being.
To participate in this trial, individuals need to be between 65 and 80 years old and have a mild form of cognitive impairment related to vascular issues or multiple causes, with symptoms that started less than a year ago. Those interested can expect to engage in various rehabilitation activities over the study period and complete assessments to track their progress. It's also important to note that individuals with certain other medical conditions or who have recently participated in similar training may not be eligible for this study. Overall, this research aims to develop better strategies for improving cognitive health in older adults facing multiple health challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age Between 65 and 80 years.
- • Neurocognitive Disorder due to vascular disease with Clinical Dementia Rating Scale score between 0.5 and 1, symptoms onset \< 12 months.
- • Neurocognitive Disorder due to multiple etiology with Clinical Dementia Rating Scale score between 0.5 and 1, symptoms onset \< 12 months.
- Exclusion Criteria:
- • Other known neurological conditions involving cognitive functioning (e.g. Parkinson's disease, Multiple Sclerosis, head trauma, alcohol abuse).
- • Severe organic instability.
- • Neoplasia in progress.
- • Severe psychiatric condition.
- • Illiteracy.
- • Severe perception deficits.
- • Severe motor disability.
- • Specific intellectual deficit.
- • Participation in other forms of training or neurostimulation in the previous 6 months.
- • Pharmacological interventions of neurological pertinence in the month before the study.
About Istituti Clinici Scientifici Maugeri Spa
Istituti Clinici Scientifici Maugeri S.p.A. is a prestigious Italian healthcare organization dedicated to advancing medical research and clinical practice. With a strong focus on patient-centered care, the institution integrates innovative clinical trials into its comprehensive services, fostering collaboration between researchers and healthcare professionals. Known for its commitment to high-quality standards and ethical practices, Istituti Clinici Scientifici Maugeri S.p.A. plays a pivotal role in the development of new therapies and treatment modalities, contributing significantly to the global medical community and enhancing patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montescano, Pavia, Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported